News
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
Eisai Co., Ltd. - Sept 27 2022Roche provides update on Alzheimer’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease
F. Hoffmann-La Roche Ltd - June 16, 2022
Could drugs prevent Alzheimer’s? These trials aim to find out
Nature - Mar 9, 2022
Blood test for Alzheimer’s highly accurate in large, international study
The Source, Washington University in St. Louis - Feb 22, 2022 First Subject Enrolled in Phase II/III Study of Eisai’s Anti-MTBR Tau Antibody E2814 for Dominantly Inherited Alzheimer’s Disease (DIAD), conducted by DIAN-TU
Eisai Co., Ltd. - Jan 19 2022
New Alzheimer’s prevention trial in young people
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
$11.5 million commitment supports new Alzheimer’s prevention clinical trial
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
International Alzheimer’s clinical trial to test two drugs in combination
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - NOV 8 2021
Global Incubator Seed Grants awarded
The Source, Washington University in St. Louis - Sept 23, 2021
The Search for a Drug to End Alzheimer’s
Some antiamyloids remove target plaques from the brain, yet don't seem to halt cognitive decline. Researchers are working to understand...
IEEE Pulse